Pregnancy after Treatment of Breast Cancer
Authors:
K. Petrakova 1,2; M. Holánek 1
Authors‘ workplace:
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
1; Lékařská fakulta MU, Brno
2
Published in:
Klin Onkol 2016; 29(Supplementum 3): 23-28
Category:
Review
doi:
https://doi.org/10.14735/amko20163S23
Overview
Thanks to improvement in cancer patients’ treatment results, growing attention has been paid to fertility issues. Physicians should discuss infertility risk and the possibilities of fertility preservation with all patients in reproductive age as soon as possible. Pregnancy in cancer survivors after adequate treatment should not be discouraged, including patients with endocrine-sensitive breast cancer. Embryo and oocyte cryopreservation are standard strategies for fertility cryopreservation. Several randomized clinical trials have addressed the role of LHRHa (luteinizing hormone-releasing hormone analogs) as a way of fertility preservation with conflicting results. A meta-analysis of clinical trials, including also the largest trials POEMS and PROMISE, showed higher odds of achieving pregnancy. These data suggest that giving LHRHa before and during adjuvant chemotherapy could also be a reliable strategy to preserve ovarian function and fertility. The use of ovarian stimulating drugs in standard treatment protocols for ovarian stimulation in female cancer patients is safe according to current data. The meta-analysis of 14 studies did not show negative influence of pregnancy on overall survival of female cancer patients although the optimal interval between breast cancer diagnosis and pregnancy is not known. However, breast cancer patients are in higher risk of preterm labor and low birth weight of infants.
Key words:
breast neoplasms – fertility preservation – ovarian stimulation – LHRH – pregnancy – tamoxifen – aromatase inhibitors – adjuvant hormonal therapy
This work was supported by MEYS – NPS I – LO1413.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted:
3. 8. 2016
Accepted:
11. 8. 2016
Sources
1. Svod.cz [internetová stránka]. Český národní webový portál epidemiologie nádorů. Masarykova univerzita, Česká republika; c2006. Dostupné z: www.svod.cz.
2. Howe HL, Wu X, Ries LA et al. Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006; 107 (8): 1711–1742.
3. Armuand GM, Rodriguez-Wallberg KA, Wettergren L et al. Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol 2012; 30 (17): 2147–2153. doi: 10.1200/JCO.2011.40. 6470.
4. Biglia N, Torrisi R, D’Alonzo M et al. Attitudes on fertility issues in breast cancer patients: an Italian survey. Gynecol Endocrinol 2015; 31 (6): 458–464. doi: 10.3109/09513590.2014.1003293.
5. Stensheim H, Cvancarova M, Møller B et al. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer 2011; 129 (5): 1225–1236. doi: 10.1002/ijc.26045.
6. Azim HA Jr, Santoro L, Pavlidis N et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer 2011; 47 (1): 74–83. doi: 10.1016/j.ejca.2010.09.007.
7. Peccatori FA, Azim HA Jr. Pregnancyin breast cancer survivors: a need for proper counseling. Breast 2009; 18 (6): 337–338. doi: 10.1016/j.breast.2009.09.014.
8. Azim HA Jr, Kroman N, Paesmans M et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013; 31 (1): 73–79. doi: 10.1200/JCO.2012.44.2285.
9. Winther JF, Olsen JH, Wu H et al. Genetic disease in the children of Danish survivors of childhood and adolescent cancer. J Clin Oncol 2012; 30 (1): 27–33. doi: 10.1200/JCO.2011.35.0504.
10. Dalberg K, Eriksson J, Holmberg L. Birth outcome in women with previously treated breast cancer – a population-based cohort study from Sweden. PLoS Med 2006; 3 (9): e336.
11. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet 2002; 360 (9328): 187–195.
12. Armuand GM, Rodriguez-Wallberg KA, Wettergren L et al. Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol 2012; 30 (17): 2147–2153. doi: 10.1200/JCO.2011.40. 6470.
13. Ruddy KJ, Gelber SI, Tamimi RM et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 2014; 32 (11): 1151–1156. doi: 10.1200/JCO.2013.52.8877.
14. Ganz PA, Land SR, Geyer CE Jr et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 2011; 29 (9): 1110–1116. doi: 10.1200/JCO.2010.29.7689.
15. Smith IE, Dowsett M, Yap YS et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006; 24 (16): 2444–2447.
16. Cakmak H, Katz A, Cedars MI et al. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 2013; 100 (6): 1673–1680. doi: 10.1016/j.fertnstert.2013.07.1992.
17. Oktay K, Hourvitz A, Sahin G et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006; 91 (10): 3885–3890.
18. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008; 26 (16): 2630–2635. doi: 10.1200/JCO.2007.14.8700.
19. Gennari A, Costa M, Puntoni M et al. Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies. Breast Cancer Res Treat 2015; 150 (2): 405–413. doi: 10.1007/s10549-015-3328-0.
20. Brinton LA, Scoccia B, Moghissi KS et al. Long-term relationship of ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomark Prev 2014; 23 (4): 584–593. doi: 10.1158/1055-9965.EPI-13-0996.
21. Del Mastro L, Boni L, Michelotti A et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011; 306 (3): 269–276. doi: 10.1001/jama.2011.991.
22. Moore HC, Unger JM, Phillips KA et al. Goserelinfor ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015; 372 (10): 923–932. doi: 10.1056/NEJMoa1413204.
23. Lambertini M, Ceppi M, Poggio F et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol 2015; 26 (12): 2408–2419.
24. Peccatori FA, Azim HA Jr, Orecchia R et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6): 160–170. doi: 10.1093/annonc/mdt 199.
25. Lambertini M, Del Maestro L, Pescio MC et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 2016; 14: 1. doi: 10.1186/s12916-015-0545-7.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2016 Issue Supplementum 3
Most read in this issue
- Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects
- Breast Cancer – Specifics of Gynecological Care and Counseling
- Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications
- Pregnancy after Treatment of Breast Cancer